Effective Medications for Treating Externalizing Disorders

  • Heather Joseph
  • Courtney Walker
  • Cristin McDermott
  • Youeun Song
  • Monique Simpson
  • Shabana KhanEmail author
Part of the Pediatric School Psychology book series (PSP)


The purpose of this chapter is to highlight the efficacy and effectiveness of psychotropic medications used in the treatment of school-aged children exhibiting externalizing behavior disorders including Attention-Deficit Hyperactivity Disorder, Oppositional Defiant Disorder, Conduct Disorder, and Intermittent Explosive Disorder. Both the intended and side effects of medication treatments (stimulants, non-stimulants, antipsychotics, mood stabilizers) commonly used to treat these externalizing disorders are reviewed. A set of references and web-based materials are provided to readers for additional information.


ADHD ODD Conduct disorder Externalizing Psychotropic medication Psychopharmacology Stimulants 


  1. Aman, M. G., Bukstein, O. G., Gadow, K. D., Arnold, L. E., Molina, B. S., McNamara, N. K., … Butter, E. M. (2014). What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder?. Journal of the American Academy of Child & Adolescent Psychiatry, 53(1), 47–60.Google Scholar
  2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (DSM-5®). American Psychiatric Pub.Google Scholar
  3. Barkley, R. A. (2014). Attention-deficit hyperactivity disorder: A handbook for diagnosis and treatment. Guilford Publications.Google Scholar
  4. Biederman, J., Monuteaux, M., Spencer, T., Wilens, T. E., & Faraone, S. V. (2009). Do stimulants have a protective effect on the development of psychiatric disorders in youth with ADHD? A ten-year follow-up study. Pediatrics, 124(1), 71–78.PubMedPubMedCentralGoogle Scholar
  5. Buitelaar, J. K., Van der Gaag, R. J., Cohen-Kettenis, P., & Melman, C. T. M. (2001). A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. Journal of Clinical Psychiatry, 62(4), 239–248.PubMedGoogle Scholar
  6. Bushe, C. J., & Savill, N. C. (2014). Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009–2011: focus on clinical efficacy and safety. Journal of Psychopharmacology, 28(3), 204–211.PubMedGoogle Scholar
  7. Campbell, M., Small, A. M., Green, W. H., Jennings, S. J., Perry, R., Bennett, W. G., & Anderson, L. (1984). Behavioral efficacy of haloperidol and lithium carbonate: a comparison in hospitalized aggressive children with conduct disorder. Archives of General Psychiatry, 41(7), 650–656.Google Scholar
  8. Canino, G., Polanczyk, G., Bauermeister, J. J., Rohde, L. A., & Frick, P. J. (2010). Does the prevalence of CD and ODD vary across cultures? Social Psychiatry and Psychiatric Epidemiology, 45(7), 695–704.PubMedPubMedCentralGoogle Scholar
  9. Coccaro, E. F., Lee, R. J., & Kavoussi, R. J. (2009). A double-blind, randomized, placebo-controlled trial of fluoxetine in patients with intermittent explosive disorder. The Journal of Clinical Psychiatry, 70(5), 653–662.PubMedGoogle Scholar
  10. Coccaro, E. F., Schmidt, C. A., Samuels, J. F., & Nestadt, G. (2004). Lifetime and 1-month prevalence rates of intermittent explosive disorder in a community sample. The Journal of Clinical Psychiatry.Google Scholar
  11. Connor, D. F. (2011). Problems of overdiagnosis and overprescribing in ADHD: are they legitimate?. Psychiatric Times, 28(8), 14–14.Google Scholar
  12. Connor, D. F., Barkely, R. A., & Davis, H. T. (2000). A pilot study of methylphenidate, clonidine or the combination in ADHD comorbid with aggressive oppositional defiant and conduct disorder. Clinical Pediatrics, 39, 15–25.PubMedGoogle Scholar
  13. Connor, D. F., McLaughlin, T. J., & Jeffers-Terry, M. (2008). Randomized controlled pilot study of quetiapine in the treatment of adolescent conduct disorder. Journal of Child and Adolescent Psychopharmacology, 18(2), 140–156.PubMedGoogle Scholar
  14. Costello, E. J., Egger, H. L., & Angold, A. (2004). Epidemiology of anxiety disorders. In Phobic and anxiety disorders in children and adolescents: A clinician’s guide to effective psychosocial and pharmacological interventions (p. 61).Google Scholar
  15. Cueva, J. E., Overall, J. E., Small, A. M., Armenteros, J. L., Perry, R., & Campbell, M. (1996). Carbamazepine in aggressive children with conduct disorder: A double-blind and placebo-controlled study. Journal of the American Academy of Child and Adolescent Psychiatry, 35(4), 480–490.PubMedGoogle Scholar
  16. Daviss, W. B. (2008). A review of co-morbid depression in pediatric ADHD: Etiologies, phenomenology, and treatment. Journal of Child and Adolescent Psychopharmacology, 18(6), 565–571.PubMedPubMedCentralGoogle Scholar
  17. Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., et al. (2000). Divaloproex treatment for youth with explosive temper and mood lability: A double-blind, placebo-controlled crossover design. American Journal of Psychiatry, 157(5), 818–820.PubMedGoogle Scholar
  18. Erskine, H. E., Norman, R. E., Ferrari, A. J., Chan, G. C., Copeland, W. E., Whiteford, H. A., et al. (2016). Long-term outcomes of attention-deficit/hyperactivity disorder and conduct disorder: a systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55(10), 841–850.PubMedGoogle Scholar
  19. Gérardin, P., Cohen, D., Mazet, P., & Flament, M. F. (2002). Drug treatment of conduct disorder in young people. European Neuropsychopharmacology, 12, 361–370.PubMedGoogle Scholar
  20. Grant, E. J., & Leppink, E. W. (2015). Choosing a treatment for disruptive, impulse-control and conduct disorders. Current Psychiatry, 14(1), 29–36.Google Scholar
  21. Greenhill, L. L., Pliszka, S., & Dulcan, M. K. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2), 26S–49S.PubMedGoogle Scholar
  22. Hazell, P. L., & Stuart, J. E. (2003). A randomized controlled trial of clonidine added to psychostimulant medication for hyperactive and aggressive children. Journal of the American Academy of Child and Adolescent Psychiatry, 42(8), 886–894.PubMedGoogle Scholar
  23. Huband, N., Ferriter, M., Nathan, R., & Jones, H. (2010). Antiepileptics for aggression and associated impulsivity. The Cochrane Library.Google Scholar
  24. Jensen, P. S. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073–1086.Google Scholar
  25. Jones, R. M., Arlidge, J., Gillham, R., Reagu, S., van den Bree, M., & Taylor, P. J. (2011). Efficacy of mood stabilisers in the treatment of impulsive or repetitive aggression: Systematic review and meta-analysis. The British Journal of Psychiatry, 198(2), 93–98.PubMedGoogle Scholar
  26. Kaplan, S. L., Busner, J., Kupietz, S., Wasserman, E., & Segal, B. (1990). Effects of methylphenidate on adolescents with aggressive conduct disorder and ADHD: A preliminary report. Journal of the American Academy of Child and Adolescent Psychiatry, 29(5), 719–723.PubMedGoogle Scholar
  27. Kapitanyan, R., & Su, M. (2016, May 5) Second generation (atypical) antipsychotic medication poisoning. UpToDate.Google Scholar
  28. Kessler, R. C., Coccaro, E. F., Fava, M., Jaeger, S., Jin, R., & Walters, E. (2006). The prevalence and correlates of DSM-IV intermittent explosive disorder in the National Comorbidity Survey Replication. Archives of General Psychiatry, 63(6), 669–678.PubMedPubMedCentralGoogle Scholar
  29. Klein, R. G., Abikoff, H., Klass, E., Ganeles, D., Seese, L. M., & Pollack, S. (1997). Clinical efficacy of methylphenidate in conduct disorder with and without attention deficit hyperactivity disorder. Archives of General Psychiatry, 54, 1073–1080.PubMedGoogle Scholar
  30. Klykylo, W., Bowers, R., Weston, C., & Jackson, J. (2014). Green’s child and adolescent clinical psychopharmacology (5th ed., p. 251). Page: Lippincott Williams & Wilkins.Google Scholar
  31. Masi, G., Milone, A., Canepa, G., Millepiedi, S., Mucci, M., & Muratori, F. (2004). Olanzapine treatment in adolescents with severe conduct disorder. European Psychiatry, 21, 51–57.Google Scholar
  32. Malone, R. P., Delaney, M. A., Luebbert, J. F., Cater, J., & Campbell, M. (2000). A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorder. Archives of General Psychiatry, 57, 649–654.PubMedGoogle Scholar
  33. Merikangas, K. R., He, J. P., Burstein, M., Swanson, S. A., Avenevoli, S., Cui, L., … Swendsen, J. (2010). Lifetime prevalence of mental disorders in US adolescents: Results from the National Comorbidity Survey Replication–Adolescent Supplement (NCS-A). Journal of the American Academy of Child & Adolescent Psychiatry, 49(10), 980–989.Google Scholar
  34. Newcorn, J. H., Spencer, T. J., Biederman, J., Milton, D. R., & Michelson, D. (2005). Atomoxetine treatment in children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 44(3), 240–248.PubMedGoogle Scholar
  35. Pappadopulos, E., MacIntyre, J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., … Felton, C. J. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. Journal of the American Academy of Child & Adolescent Psychiatry, 42(2), 145–161.Google Scholar
  36. Pappadopulos, E., Woolston, S., Chait, A., Perkins, M., Connor, D. F., & Jensen, P. S. (2006). Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. Journal of the Canadian Academy of Child and Adolescent Psychiatry, 15(1), 27–39.PubMedPubMedCentralGoogle Scholar
  37. Pliszka, S., AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(7), 894–921.Google Scholar
  38. Pliszka, S. R., Crismon, M. L., Hughes, C. W., Corners, C. K., Emslie, G. J., & Jensen, P. S. (2006). The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45(6), 642–657.PubMedGoogle Scholar
  39. Rifkin, A., Karajgi, B., Dicker, R., Perl, E., Boppana, V., Hasan, N., et al. (1997). Lithium treatment of conduct disorder in adolescents. American Journal of Psychiatry, 154(4), 554–555.PubMedGoogle Scholar
  40. Schachter, S. (2017, February 27) Antiseizure drugs: mechanism of action, pharmacology and adverse effects. UpToDate.Google Scholar
  41. Sheard, M. H., Marini, J. L., Bridges, C. I., & Wagner, E. (1976). The effect of lithium on impulsive aggressive behavior in man. American Journal of Psychiatry, 133(12), 1409–1413.PubMedGoogle Scholar
  42. Siever, L. J. (2008). Neurobiology of aggression and violence. American Journal of Psychiatry, 165(4), 429–442.PubMedGoogle Scholar
  43. Soderstrom, H., Rastam, M., & Gilberg, C. (2002). A clinical case series of six extremely aggressive youths treated with olanzapine. European Child and Adolescent Psychiatry, 11, 138–141.PubMedGoogle Scholar
  44. Stanford, M. S., Anderson, N. E., Lake, S. L., & Baldridge, R. M. (2009). Pharmacologic treatment of impulsive aggression with antiepileptic drugs. Current treatment options in neurology, 11(5), 383–390.PubMedGoogle Scholar
  45. Steiner, H., & Remsing, L. (2007). Practice parameter for the assessment and treatment of children and adolescents with oppositional defiant disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 46(1), 126–141.PubMedGoogle Scholar
  46. Turgay, A. (2009). Psychopharmacological treatment of oppositional defiant disorder. CNS Drugs, 23(1), 1–17.PubMedGoogle Scholar
  47. Volkow, N. D., Wang, G. J., Tomasi, D., Kollins, S. H., Wigal, T. L., Newcorn, J. H., … Swanson, J. M. (2012). Methylphenidate-elicited dopamine increases in ventral striatum are associated with long-term symptom improvement in adults with attention deficit hyperactivity disorder. Journal of Neuroscience, 32(3), 841–849.PubMedGoogle Scholar
  48. Zuvekas, S. H., & Vitiello, B. (2012). Stimulant medication use in children: A 12-year perspective. American Journal of Psychiatry, 169(2), 160–166.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Heather Joseph
    • 1
  • Courtney Walker
    • 1
  • Cristin McDermott
    • 1
  • Youeun Song
    • 1
  • Monique Simpson
    • 1
  • Shabana Khan
    • 1
    Email author
  1. 1.School of MedicineUniversity of PittsburghPittsburghUSA

Personalised recommendations